Targeted and Synergistic Codelivery of Chemotherapeutic and Nucleic Acid Drugs by Liposome-Coated MPDA Nanoparticles for Advanced Prostate Cancer Treatment

• Published in: ACS applied materials & interfaces Vol. 17; no. 6; pp. 8875 - 8885
• Main Authors: Dai, Liang, Ma, Wangteng, Song, Zixuan, Lu, Binwei, He, Yuchu, Zhang, Jidong, Wei, Dapeng, Wang, Baibing, Li, Guangming, Gao, Dawei, Wang, Yimin
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 12.02.2025
• Subjects: Animals; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Biological and Medical Applications of Materials and Interfaces; cancer therapy; cell growth; Cell Line, Tumor; Cell Proliferation - drug effects; Docetaxel - chemistry; Docetaxel - pharmacology; Docetaxel - therapeutic use; Drug Delivery Systems; drug therapy; Fourier transform infrared spectroscopy; Humans; hypersensitivity; immunosuppression; Indoles - chemistry; Liposomes - chemistry; Male; Mice; nanoparticles; Nanoparticles - chemistry; neurotoxicity; nucleic acids; oligonucleotides; polyethylene glycol; Polyethylene Glycols - chemistry; Polymers - chemistry; porous media; prostatic neoplasms; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - pathology; RNA, Small Interfering - chemistry; RNA, Small Interfering - pharmacology; transmission electron microscopy; targeted drug delivery; synergy therapy; prostate cancer; mesoporous polydopamine nanoparticles; aptamer

Docetaxel (DTX)-based chemotherapy is the primary therapeutic approach for advanced prostate cancer (PCa) when endocrine therapy proves ineffective. Traditional chemotherapy exhibits poor specificity and induces severe side effects, such as immunosuppression, neurotoxicity, and hypersensitivity. In...